Literature DB >> 12414953

Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.

Catherine M Finnegan1, Werner Berg, George K Lewis, Anthony L DeVico.   

Abstract

Human immunodeficiency virus (HIV) entry is triggered by interactions between a pair of heptad repeats in the gp41 ectodomain, which convert a prehairpin gp41 trimer into a fusogenic three-hairpin bundle. Here we examined the disposition and antigenic nature of these structures during the HIV-mediated fusion of HeLa cells expressing either HIV(HXB2) envelope (Env cells) or CXCR4 and CD4 (target cells). Cell-cell fusion, indicated by cytoplasmic dye transfer, was allowed to progress for various lengths of time and then arrested. Fusion intermediates were then examined for reactivity with various monoclonal antibodies (MAbs) against immunogenic cluster I and cluster II epitopes in the gp41 ectodomain. All of these MAbs produced similar staining patterns indicative of reactivity with prehairpin gp41 intermediates or related structures. MAb staining was seen on Env cells only upon exposure to soluble CD4, CD4-positive, coreceptor-negative cells, or stromal cell-derived factor-treated target cells. In the fusion system, the MAbs reacted with the interfaces of attached Env and target cells within 10 min of coculture. MAb reactivity colocalized with the formation of gp120-CD4-coreceptor tricomplexes after longer periods of coculture, although reactivity was absent on cells exhibiting cytoplasmic dye transfer. Notably, the MAbs were unable to inhibit fusion even when allowed to react with soluble-CD4-triggered or temperature-arrested antigens prior to initiation of the fusion process. In comparison, a broadly neutralizing antibody, 2F5, which recognizes gp41 antigens in the HIV envelope spike, was immunoreactive with free Env cells and Env-target cell clusters but not with fused cells. Notably, exposure of the 2F5 epitope required temperature-dependent elements of the HIV envelope structure, as MAb binding occurred only above 19 degrees C. Overall, these results demonstrate that immunogenic epitopes, both neutralizing and nonneutralizing, are accessible on gp41 antigens prior to membrane fusion. The 2F5 epitope appears to depend on temperature-dependent elements on prefusion antigens, whereas cluster I and cluster II epitopes are displayed by transient gp41 structures. Such findings have important implications for HIV vaccine approaches based on gp41 intermediates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12414953      PMCID: PMC136862          DOI: 10.1128/jvi.76.23.12123-12134.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

Review 1.  HIV entry and its inhibition.

Authors:  D C Chan; P S Kim
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

2.  Atomic structure of a thermostable subdomain of HIV-1 gp41.

Authors:  K Tan; J Liu; J Wang; S Shen; M Lu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

3.  Atomic structure of the ectodomain from HIV-1 gp41.

Authors:  W Weissenhorn; A Dessen; S C Harrison; J J Skehel; D C Wiley
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

4.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

5.  Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors.

Authors:  P L Jones; T Korte; R Blumenthal
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

6.  Capture of an early fusion-active conformation of HIV-1 gp41.

Authors:  R A Furuta; C T Wild; Y Weng; C D Weiss
Journal:  Nat Struct Biol       Date:  1998-04

7.  Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41.

Authors:  I Muñoz-Barroso; S Durell; K Sakaguchi; E Appella; R Blumenthal
Journal:  J Cell Biol       Date:  1998-01-26       Impact factor: 10.539

8.  Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.

Authors:  B A Watkins; S Buge; K Aldrich; A E Davis; J Robinson; M S Reitz; M Robert-Guroff
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

9.  Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group.

Authors:  M P D'Souza; D Livnat; J A Bradac; S H Bridges
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

10.  Spontaneous and ligand-induced trafficking of CXC-chemokine receptor 4.

Authors:  N I Tarasova; R H Stauber; C J Michejda
Journal:  J Biol Chem       Date:  1998-06-26       Impact factor: 5.157

View more
  40 in total

1.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.

Authors:  Antony S Dimitrov; John M Louis; Carole A Bewley; G Marius Clore; Robert Blumenthal
Journal:  Biochemistry       Date:  2005-09-20       Impact factor: 3.162

3.  The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.

Authors:  Abraham Pinter; William J Honnen; Paul D'Agostino; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

4.  Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.

Authors:  Florence M Brunel; Michael B Zwick; Rosa M F Cardoso; Josh D Nelson; Ian A Wilson; Dennis R Burton; Philip E Dawson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Time frames for neutralization during the human immunodeficiency virus type 1 entry phase, as monitored in synchronously infected cell cultures.

Authors:  Hillel Haim; Israel Steiner; Amos Panet
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

6.  A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.

Authors:  Gary Frey; Hanqin Peng; Sophia Rits-Volloch; Marco Morelli; Yifan Cheng; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-05       Impact factor: 11.205

7.  Identification of the LWYIK motif located in the human immunodeficiency virus type 1 transmembrane gp41 protein as a distinct determinant for viral infection.

Authors:  Steve S-L Chen; Polung Yang; Po-Yuan Ke; Hsiao-Fen Li; Woan-Eng Chan; Ding-Kwo Chang; Chin-Kai Chuang; Yu Tsai; Shu-Chen Huang
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

8.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Authors:  Thomas J Ketas; Sophie Holuigue; Katie Matthews; John P Moore; Per Johan Klasse
Journal:  Virology       Date:  2011-10-22       Impact factor: 3.616

9.  Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes.

Authors:  Nobuyuki Matoba; Tagan A Griffin; Michele Mittman; Jeffrey D Doran; Annette Alfsen; David C Montefiori; Carl V Hanson; Morgane Bomsel; Tsafrir S Mor
Journal:  Curr HIV Res       Date:  2008-05       Impact factor: 1.581

10.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.